GHCM
IMMU

Glen Harbor Capital Management’s Immunomedics Inc IMMU Stock Holding History

Glen Harbor Capital Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,652
Closed -$38K – 1329
2018
Q4 		$38K Buy
+2,652
New +$52.6K ﹤0.01% 1199

Other funds holding IMMU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Glen Harbor Capital Management's IMMU Position: Q1 2019 in Review

Glen Harbor Capital Management sold out of Immunomedics Inc (IMMU) in Q1 2019, closing a stake of 2,652 shares — an estimated $38K sold.

Glen Harbor Capital Management first reported a position in IMMU in Q4 2018 and held it in 1 quarter. The position peaked at $38K in Q4 2018. 204 funds tracked by Wall St. Rank hold IMMU as of Q1 2019.

  • Glen Harbor Capital Management reported no remaining Immunomedics Inc position as of Q1 2019 after selling out during the quarter.
  • Glen Harbor Capital Management sold 2,652 Immunomedics Inc shares in Q1 2019, an estimated $38K.
  • Glen Harbor Capital Management first reported a position in Immunomedics Inc in Q4 2018 and held it in 1 quarter.
  • Glen Harbor Capital Management's Immunomedics Inc position peaked at $38K in Q4 2018.
  • 204 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2019.

Based on Glen Harbor Capital Management's 13F filing for Q1 2019, filed 13 May 2019.